关于我们
关于HLB
领导寄语
沿革
地位
集团
制药,生物科技
造船
生活·健康·餘暇活動
金融
事业
制药,生物科技
细胞毒性药物
靶向治疗药物
免疫疗法
特殊船舶
GRE PIPE事业
投资者关系
股价信息
公司公告
公关
IR LETTER
报刊
资料室
职业
招聘
中文
韩文
英文
home
Title + Content
主题+内容
主题
内容
探索
顺序
主题
题目
日子
88
HLB to present results of rivoceranib at global lung cancer meeting
admin
2021.09.02
87
Hwajin, a subsidiary of HLB, gained the U.S. FDA's approval for Sofjec syringes
admin
2021.08.24
86
Elevar Therapeutics Announces Orphan Drug Designation for Rivoceranib (Apatinib) for the Treatment of Adenoid Cystic Carcinoma (ACC)
admin
2021.02.09
85
Elevar Therapeutics announces Licensing Agreement with Inceptua Group for commercialization of Apealea® (Paclitaxel Micellar) in Europe
admin
2020.12.27
84
Rivoceranib showed 'complete remission' in a combination clinical trial of refractory hepatocellular carcinoma.
admin
2020.12.10
83
HLB confirms "excellent treatment effect for breeding” in combination therapy of Rivoceranib and Opdivo
admin
2020.11.20
82
Elevar Therapeutics announces Early Completion of Initial Target Enrollment in Pivotal Phase 2 Study Evaluating Rivoceranib (Apatinib) in Adenoid Cystic Cancer (ACC)
admin
2020.11.18
81
Rivoceranib gets the 'Approval for Therapeutic Use' for Terminal Gastric Cancer Patients
admin
2020.10.21
80
Rivoceranib selected as a 'Highlight' of ESMO 2020 by the European Association
admin
2020.10.07
79
Elevar Therapeutics and Taiba Middle East Fz Llc Partner to commercialize Apealea® (Paclitaxel Micellar) in the Middle East and North Africa region
admin
2020.10.06
1
2
3
4
5
6
7
8
9
10
>
>>